NYMC Faculty Publications
Asenapine Review, Part II: Clinical Efficacy, Safety and Tolerability
Author Type(s)
Faculty
DOI
10.1517/14740338.2014.908183
Journal Title
Expert Opinion on Drug Safety
First Page
803
Last Page
830
Document Type
Article
Publication Date
6-1-2014
Department
Psychiatry and Behavioral Sciences
Keywords
Antipsychotic Agents, Bipolar Disorder, Dibenzocycloheptenes, Electrocardiography, Heterocyclic Compounds, 4 or More Rings, Humans, Schizophrenia
Disciplines
Medicine and Health Sciences
Abstract
INTRODUCTION: Asenapine is a second-generation (atypical) antipsychotic currently marketed for the treatment of schizophrenia and bipolar mania/mixed episodes.
AREAS COVERED: The purpose of this review is to describe the clinical profile of asenapine.
EXPERT OPINION: Asenapine's efficacy in the treatment of schizophrenia and in the acute management of bipolar manic or mixed episodes, within the recommended therapeutic dose range of 5 - 10 mg twice a day, is evidenced by a broad clinical development program. Asenapine's overall tolerability profile is notable for the potential for sedation (time-limited) and, to a lesser extent, extrapyramidal symptoms/akathisia, dizziness, and oral hypoesthesia. Asenapine's effects on weight and metabolic variables appear modest, as are its effects on the ECG QTc interval and on prolactin.
Recommended Citation
Citrome, L. (2014). Asenapine Review, Part II: Clinical Efficacy, Safety and Tolerability. Expert Opinion on Drug Safety, 13 (6), 803-830. https://doi.org/10.1517/14740338.2014.908183
